$AGN Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Allergan plc.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Allergan plc. Get notifications about new insider transactions in Allergan plc for free.
Page: < prev 1 2 3 4 5 5 next >
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Mar 04 2020 | AGN | Allergan plc | Meury William | EVP & Chief Commerc ... | Grant | A | 193.84 | 21,667 | 4,199,931 | 33,490 | 11.8 K to 33.5 K (+183.26 %) |
Mar 04 2020 | AGN | Allergan plc | Bailey A Robert D | EVP Chief Legal Off ... | Grant | A | 193.84 | 14,444 | 2,799,825 | 35,008 | 20.6 K to 35 K (+70.24 %) |
Mar 04 2020 | AGN | Allergan plc | WALSH MATTHEW M | EVP, Chief Financia ... | Grant | A | 193.84 | 15,476 | 2,999,868 | 39,657 | 24.2 K to 39.7 K (+64.00 %) |
Mar 04 2020 | AGN | Allergan plc | SAUNDERS BRENT L | Chairman, President ... | Grant | A | 193.84 | 68,613 | 13,299,944 | 229,189 | 160.6 K to 229.2 K (+42.73 %) |
Jan 02 2020 | AGN | Allergan plc | Swanton Wayne R | EVP, Global Operati ... | Payment of Exercise | F | 191.17 | 146 | 27,911 | 12,394 | 12.5 K to 12.4 K (-1.16 %) |
Jan 02 2020 | AGN | Allergan plc | Nicholson C. David | EVP Chief R&D Offic ... | Payment of Exercise | F | 191.17 | 1,031 | 197,096 | 14,305 | 15.3 K to 14.3 K (-6.72 %) |
Jan 02 2020 | AGN | Allergan plc | Meury William | EVP & Chief Commerc ... | Payment of Exercise | F | 191.17 | 1,504 | 287,520 | 11,823 | 13.3 K to 11.8 K (-11.29 %) |
Jan 02 2020 | AGN | Allergan plc | DArecca James | SVP Chief Accountin ... | Payment of Exercise | F | 191.17 | 92 | 17,588 | 6,941 | 7 K to 6.9 K (-1.31 %) |
Jan 02 2020 | AGN | Allergan plc | Bailey A Robert D | EVP Chief Legal Off ... | Payment of Exercise | F | 191.17 | 1,313 | 251,006 | 20,564 | 21.9 K to 20.6 K (-6.00 %) |
Jan 02 2020 | AGN | Allergan plc | SAUNDERS BRENT L | Chairman, President ... | Payment of Exercise | F | 191.17 | 7,333 | 1,401,850 | 160,576 | 167.9 K to 160.6 K (-4.37 %) |
Dec 16 2019 | AGN | Allergan plc | Swanton Wayne R | EVP, Global Operati ... | Payment of Exercise | F | 188.27 | 488 | 91,876 | 12,540 | 13 K to 12.5 K (-3.75 %) |
Dec 09 2019 | AGN | Allergan plc | Basgoz Nesli | Director | Gift | G | 0.00 | 47 | 0 | 8,160 | 8.2 K to 8.2 K (-0.57 %) |
May 02 2019 | AGN | Allergan plc | COUGHLIN CHRISTOPHER J | Director | Grant | A | 145.33 | 2,064 | 299,961 | 17,080 | 15 K to 17.1 K (+13.75 %) |
May 02 2019 | AGN | Allergan plc | COUGHLIN CHRISTOPHER J | Director | Payment of Exercise | F | 147.00 | 953 | 140,091 | 15,016 | 16 K to 15 K (-5.97 %) |
May 02 2019 | AGN | Allergan plc | McDonnell Peter J | Director | Grant | A | 145.33 | 2,064 | 299,961 | 7,343 | 5.3 K to 7.3 K (+39.10 %) |
May 02 2019 | AGN | Allergan plc | McDonnell Peter J | Director | Payment of Exercise | F | 147.00 | 953 | 140,091 | 5,279 | 6.2 K to 5.3 K (-15.29 %) |
May 02 2019 | AGN | Allergan plc | KLEMA CATHY | Director | Payment of Exercise | F | 147.00 | 953 | 140,091 | 25,081 | 26 K to 25.1 K (-3.66 %) |
May 02 2019 | AGN | Allergan plc | McDonnell Peter J | Director | Grant | A | 145.33 | 2,064 | 299,961 | 7,343 | 5.3 K to 7.3 K (+39.10 %) |
May 02 2019 | AGN | Allergan plc | McDonnell Peter J | Director | Payment of Exercise | F | 147.00 | 953 | 140,091 | 5,279 | 6.2 K to 5.3 K (-15.29 %) |
May 02 2019 | AGN | Allergan plc | KLEMA CATHY | Director | Payment of Exercise | F | 147.00 | 953 | 140,091 | 25,081 | 26 K to 25.1 K (-3.66 %) |
May 02 2019 | AGN | Allergan plc | HUGIN ROBERT J | Director | Grant | A | 145.33 | 2,064 | 299,961 | 5,285 | 3.2 K to 5.3 K (+64.08 %) |
May 02 2019 | AGN | Allergan plc | HUGIN ROBERT J | Director | Payment of Exercise | F | 147.00 | 205 | 30,135 | 3,221 | 3.4 K to 3.2 K (-5.98 %) |
May 02 2019 | AGN | Allergan plc | Greenberg Michael Eldon | Director | Grant | A | 145.33 | 2,064 | 299,961 | 2,684 | 620 to 2.7 K (+332.90 %) |
May 02 2019 | AGN | Allergan plc | Greenberg Michael Eldon | Director | Payment of Exercise | F | 147.00 | 574 | 84,378 | 620 | 1.2 K to 620 (-48.07 %) |
May 02 2019 | AGN | Allergan plc | HUGIN ROBERT J | Director | Grant | A | 145.33 | 2,064 | 299,961 | 5,285 | 3.2 K to 5.3 K (+64.08 %) |
May 02 2019 | AGN | Allergan plc | HUGIN ROBERT J | Director | Payment of Exercise | F | 147.00 | 205 | 30,135 | 3,221 | 3.4 K to 3.2 K (-5.98 %) |
May 02 2019 | AGN | Allergan plc | FREYMAN THOMAS C | Director | Grant | A | 145.33 | 2,064 | 299,961 | 3,974 | 1.9 K to 4 K (+108.06 %) |
May 02 2019 | AGN | Allergan plc | FREYMAN THOMAS C | Director | Payment of Exercise | F | 147.00 | 748 | 109,956 | 1,910 | 2.7 K to 1.9 K (-28.14 %) |
May 02 2019 | AGN | Allergan plc | Greenberg Michael Eldon | Director | Grant | A | 145.33 | 2,064 | 299,961 | 2,684 | 620 to 2.7 K (+332.90 %) |
May 02 2019 | AGN | Allergan plc | Greenberg Michael Eldon | Director | Payment of Exercise | F | 147.00 | 574 | 84,378 | 620 | 1.2 K to 620 (-48.07 %) |
May 02 2019 | AGN | Allergan plc | FREYMAN THOMAS C | Director | Grant | A | 145.33 | 2,064 | 299,961 | 3,974 | 1.9 K to 4 K (+108.06 %) |
May 02 2019 | AGN | Allergan plc | FREYMAN THOMAS C | Director | Payment of Exercise | F | 147.00 | 748 | 109,956 | 1,910 | 2.7 K to 1.9 K (-28.14 %) |
May 02 2019 | AGN | Allergan plc | Brown Adriane M | Director | Grant | A | 145.33 | 2,064 | 299,961 | 3,907 | 1.8 K to 3.9 K (+111.99 %) |
May 02 2019 | AGN | Allergan plc | Brown Adriane M | Director | Payment of Exercise | F | 147.00 | 953 | 140,091 | 1,843 | 2.8 K to 1.8 K (-34.08 %) |
May 02 2019 | AGN | Allergan plc | Boccuzi Joseph H | Director | Grant | A | 145.33 | 2,064 | 299,961 | 4,596 | 2.5 K to 4.6 K (+81.52 %) |
May 02 2019 | AGN | Allergan plc | Boccuzi Joseph H | Director | Payment of Exercise | F | 147.00 | 953 | 140,091 | 2,532 | 3.5 K to 2.5 K (-27.35 %) |
May 02 2019 | AGN | Allergan plc | Basgoz Nesli | Director | Grant | A | 145.33 | 2,064 | 299,961 | 8,207 | 6.1 K to 8.2 K (+33.60 %) |
May 02 2019 | AGN | Allergan plc | Basgoz Nesli | Director | Payment of Exercise | F | 147.00 | 953 | 140,091 | 6,143 | 7.1 K to 6.1 K (-13.43 %) |
May 02 2019 | AGN | Allergan plc | Brown Adriane M | Director | Grant | A | 145.33 | 2,064 | 299,961 | 3,907 | 1.8 K to 3.9 K (+111.99 %) |
May 02 2019 | AGN | Allergan plc | Brown Adriane M | Director | Payment of Exercise | F | 147.00 | 953 | 140,091 | 1,843 | 2.8 K to 1.8 K (-34.08 %) |
May 02 2019 | AGN | Allergan plc | Boccuzi Joseph H | Director | Grant | A | 145.33 | 2,064 | 299,961 | 4,596 | 2.5 K to 4.6 K (+81.52 %) |
May 02 2019 | AGN | Allergan plc | Boccuzi Joseph H | Director | Payment of Exercise | F | 147.00 | 953 | 140,091 | 2,532 | 3.5 K to 2.5 K (-27.35 %) |
May 02 2019 | AGN | Allergan plc | Basgoz Nesli | Director | Grant | A | 145.33 | 2,064 | 299,961 | 8,207 | 6.1 K to 8.2 K (+33.60 %) |
May 02 2019 | AGN | Allergan plc | Basgoz Nesli | Director | Payment of Exercise | F | 147.00 | 953 | 140,091 | 6,143 | 7.1 K to 6.1 K (-13.43 %) |
Apr 05 2019 | AGN | Allergan plc | Meury William | EVP & Chief Commerc ... | Payment of Exercise | F | 145.71 | 871 | 126,913 | 13,327 | 14.2 K to 13.3 K (-6.13 %) |
Apr 05 2019 | AGN | Allergan plc | Nicholson C. David | EVP Chief R&D Offic ... | Payment of Exercise | F | 145.71 | 871 | 126,913 | 15,336 | 16.2 K to 15.3 K (-5.37 %) |
Apr 05 2019 | AGN | Allergan plc | SAUNDERS BRENT L | Chairman, President ... | Payment of Exercise | F | 145.71 | 2,757 | 401,722 | 167,909 | 170.7 K to 167.9 K (-1.62 %) |
Apr 05 2019 | AGN | Allergan plc | Ling Karen | EVP & Chief H.R. Of ... | Payment of Exercise | F | 145.71 | 394 | 57,410 | 25,132 | 25.5 K to 25.1 K (-1.54 %) |
Apr 05 2019 | AGN | Allergan plc | Bailey A Robert D | EVP Chief Legal Off ... | Payment of Exercise | F | 145.71 | 581 | 84,658 | 21,877 | 22.5 K to 21.9 K (-2.59 %) |
Mar 19 2019 | AGN | Allergan plc | Swanton Wayne R | EVP, Global Operati ... | Payment of Exercise | F | 151.25 | 41 | 6,201 | 13,028 | 13.1 K to 13 K (-0.31 %) |
Mar 13 2019 | AGN | Allergan plc | KLEMA CATHY | Director | Buy | J | 0.00 | 410 | 0 | 26,034 | 25.6 K to 26 K (+1.60 %) |
Mar 11 2019 | AGN | Allergan plc | DArecca James | SVP Chief Accountin ... | Payment of Exercise | F | 145.06 | 113 | 16,392 | 7,033 | 7.1 K to 7 K (-1.58 %) |
Mar 11 2019 | AGN | Allergan plc | DArecca James | SVP Chief Accountin ... | Payment of Exercise | F | 143.00 | 359 | 51,337 | 7,146 | 7.5 K to 7.1 K (-4.78 %) |
Mar 11 2019 | AGN | Allergan plc | Swanton Wayne R | EVP, Global Operati ... | Payment of Exercise | F | 145.06 | 130 | 18,858 | 13,069 | 13.2 K to 13.1 K (-0.98 %) |
Mar 11 2019 | AGN | Allergan plc | Swanton Wayne R | EVP, Global Operati ... | Payment of Exercise | F | 143.00 | 155 | 22,165 | 13,199 | 13.4 K to 13.2 K (-1.16 %) |
Mar 08 2019 | AGN | Allergan plc | DArecca James | SVP Chief Accountin ... | Grant | A | 137.51 | 2,036 | 279,970 | 7,505 | 5.5 K to 7.5 K (+37.23 %) |
Mar 07 2019 | AGN | Allergan plc | SAUNDERS BRENT L | Chairman, President ... | Buy | P | 144.37 | 600 | 86,622 | 170,666 | 170.1 K to 170.7 K (+0.35 %) |
Mar 07 2019 | AGN | Allergan plc | SAUNDERS BRENT L | Chairman, President ... | Buy | P | 143.70 | 860 | 123,582 | 170,066 | 169.2 K to 170.1 K (+0.51 %) |
Mar 07 2019 | AGN | Allergan plc | SAUNDERS BRENT L | Chairman, President ... | Buy | P | 142.18 | 300 | 42,654 | 169,206 | 168.9 K to 169.2 K (+0.18 %) |
Mar 06 2019 | AGN | Allergan plc | Swanton Wayne R | EVP, Global Operati ... | Payment of Exercise | F | 139.12 | 85 | 11,825 | 13,354 | 13.4 K to 13.4 K (-0.63 %) |
Mar 06 2019 | AGN | Allergan plc | DArecca James | SVP Chief Accountin ... | Payment of Exercise | F | 139.12 | 114 | 15,860 | 5,469 | 5.6 K to 5.5 K (-2.04 %) |
Feb 21 2019 | AGN | Allergan plc | WALSH MATTHEW M | EVP, Chief Financia ... | Payment of Exercise | F | 140.33 | 2,235 | 313,638 | 24,181 | 26.4 K to 24.2 K (-8.46 %) |
Feb 20 2019 | AGN | Allergan plc | HUGIN ROBERT J | Director | Grant | A | 139.07 | 426 | 59,244 | 3,426 | 3 K to 3.4 K (+14.20 %) |
Jan 03 2019 | AGN | Allergan plc | Swanton Wayne R | EVP, Global Operati ... | Payment of Exercise | F | 133.66 | 163 | 21,787 | 15,806 | 16 K to 15.8 K (-1.02 %) |
Jan 03 2019 | AGN | Allergan plc | SAUNDERS BRENT L | Chairman, President ... | Payment of Exercise | F | 133.66 | 9,269 | 1,238,895 | 168,906 | 178.2 K to 168.9 K (-5.20 %) |
Jan 03 2019 | AGN | Allergan plc | Nicholson C. David | EVP Chief R&D Offic ... | Payment of Exercise | F | 133.66 | 1,150 | 153,709 | 16,207 | 17.4 K to 16.2 K (-6.63 %) |
Jan 03 2019 | AGN | Allergan plc | Meury William | EVP & Chief Commerc ... | Payment of Exercise | F | 133.66 | 1,531 | 204,633 | 14,198 | 15.7 K to 14.2 K (-9.73 %) |
Jan 03 2019 | AGN | Allergan plc | Ling Karen | EVP & Chief H.R. Of ... | Payment of Exercise | F | 133.66 | 1,240 | 165,738 | 25,526 | 26.8 K to 25.5 K (-4.63 %) |
Jan 03 2019 | AGN | Allergan plc | DArecca James | SVP Chief Accountin ... | Payment of Exercise | F | 133.66 | 147 | 19,648 | 5,453 | 5.6 K to 5.5 K (-2.62 %) |
Jan 03 2019 | AGN | Allergan plc | Bailey A Robert D | EVP Chief Legal Off ... | Payment of Exercise | F | 133.66 | 1,464 | 195,678 | 22,458 | 23.9 K to 22.5 K (-6.12 %) |
Dec 14 2018 | AGN | Allergan plc | Swanton Wayne R | EVP, Global Operati ... | Payment of Exercise | F | 152.27 | 544 | 82,835 | 15,969 | 16.5 K to 16 K (-3.29 %) |
Nov 19 2018 | AGN | Allergan plc | WALSH MATTHEW M | EVP, Chief Financia ... | Buy | P | 157.00 | 1,000 | 157,000 | 26,416 | 25.4 K to 26.4 K (+3.93 %) |
Sep 07 2018 | AGN | Allergan plc | COUGHLIN CHRISTOPHER J | Director | Buy | P | 190.63 | 300 | 57,189 | 16,431 | 16.1 K to 16.4 K (+1.86 %) |
Sep 07 2018 | AGN | Allergan plc | COUGHLIN CHRISTOPHER J | Director | Buy | P | 190.64 | 517 | 98,561 | 16,131 | 15.6 K to 16.1 K (+3.31 %) |
Sep 07 2018 | AGN | Allergan plc | COUGHLIN CHRISTOPHER J | Director | Buy | P | 190.68 | 4,889 | 932,235 | 15,614 | 10.7 K to 15.6 K (+45.59 %) |
Sep 07 2018 | AGN | Allergan plc | COUGHLIN CHRISTOPHER J | Director | Buy | P | 190.67 | 222 | 42,329 | 10,725 | 10.5 K to 10.7 K (+2.11 %) |
Sep 07 2018 | AGN | Allergan plc | COUGHLIN CHRISTOPHER J | Director | Buy | P | 190.66 | 816 | 155,579 | 10,503 | 9.7 K to 10.5 K (+8.42 %) |
Sep 07 2018 | AGN | Allergan plc | COUGHLIN CHRISTOPHER J | Director | Buy | P | 190.65 | 100 | 19,065 | 9,687 | 9.6 K to 9.7 K (+1.04 %) |
Sep 07 2018 | AGN | Allergan plc | COUGHLIN CHRISTOPHER J | Director | Buy | P | 190.62 | 68 | 12,962 | 9,587 | 9.5 K to 9.6 K (+0.71 %) |
Sep 07 2018 | AGN | Allergan plc | COUGHLIN CHRISTOPHER J | Director | Buy | P | 190.61 | 200 | 38,122 | 9,519 | 9.3 K to 9.5 K (+2.15 %) |
Sep 07 2018 | AGN | Allergan plc | COUGHLIN CHRISTOPHER J | Director | Buy | P | 190.60 | 400 | 76,240 | 9,319 | 8.9 K to 9.3 K (+4.48 %) |
Sep 07 2018 | AGN | Allergan plc | COUGHLIN CHRISTOPHER J | Director | Buy | P | 190.59 | 356 | 67,850 | 8,919 | 8.6 K to 8.9 K (+4.16 %) |
Sep 07 2018 | AGN | Allergan plc | COUGHLIN CHRISTOPHER J | Director | Buy | P | 190.58 | 100 | 19,058 | 8,563 | 8.5 K to 8.6 K (+1.18 %) |
Sep 07 2018 | AGN | Allergan plc | COUGHLIN CHRISTOPHER J | Director | Buy | P | 190.57 | 27 | 5,145 | 8,463 | 8.4 K to 8.5 K (+0.32 %) |
Sep 07 2018 | AGN | Allergan plc | COUGHLIN CHRISTOPHER J | Director | Buy | P | 190.56 | 705 | 134,345 | 8,436 | 7.7 K to 8.4 K (+9.12 %) |
Sep 07 2018 | AGN | Allergan plc | COUGHLIN CHRISTOPHER J | Director | Buy | P | 190.55 | 1,300 | 247,715 | 7,731 | 6.4 K to 7.7 K (+20.21 %) |
Sep 04 2018 | AGN | Allergan plc | Basgoz Nesli | Director | Gift | G | 0.00 | 263 | 0 | 7,096 | 7.4 K to 7.1 K (-3.57 %) |
Sep 04 2018 | AGN | Allergan plc | Basgoz Nesli | Director | Sell | S | 190.05 | 1,055 | 200,503 | 7,359 | 8.4 K to 7.4 K (-12.54 %) |
Sep 04 2018 | AGN | Allergan plc | FREYMAN THOMAS C | Director | Buy | P | 190.69 | 1,100 | 209,759 | 2,658 | 1.6 K to 2.7 K (+70.60 %) |
Sep 04 2018 | AGN | Allergan plc | Boccuzi Joseph H | Director | Buy | P | 190.59 | 900 | 171,531 | 3,885 | 3 K to 3.9 K (+30.15 %) |
Aug 14 2018 | AGN | Allergan plc | Basgoz Nesli | Director | Option Exercise | M | 81.16 | 1,889 | 153,311 | 0 | |
Aug 14 2018 | AGN | Allergan plc | Basgoz Nesli | Director | Payment of Exercise | F | 184.00 | 834 | 153,456 | 8,414 | 9.2 K to 8.4 K (-9.02 %) |
Aug 14 2018 | AGN | Allergan plc | Basgoz Nesli | Director | Buy | M | 81.16 | 1,889 | 153,311 | 9,248 | 7.4 K to 9.2 K (+25.67 %) |
Aug 08 2018 | AGN | Allergan plc | Greenberg Michael Eldon | Director | Grant | A | 184.88 | 1,194 | 220,747 | 1,194 | 0 to 1.2 K |
Jul 25 2018 | AGN | Allergan plc | Ling Karen | Chief Human Resourc ... | Payment of Exercise | F | 172.23 | 715 | 123,144 | 26,766 | 27.5 K to 26.8 K (-2.60 %) |
Jun 15 2018 | AGN | Allergan plc | FREYMAN THOMAS C | Director | Grant | A | 170.23 | 1,558 | 265,218 | 1,558 | 0 to 1.6 K |
May 21 2018 | AGN | Allergan plc | Meury William | EVP & Chief Commerc ... | Option Exercise | M | 68.11 | 19,785 | 1,347,556 | 0 | |
May 21 2018 | AGN | Allergan plc | Meury William | EVP & Chief Commerc ... | Option Exercise | M | 68.11 | 1,467 | 99,917 | 0 | |
May 21 2018 | AGN | Allergan plc | Meury William | EVP & Chief Commerc ... | Sell | S | 154.59 | 24,425 | 3,775,861 | 15,729 | 40.2 K to 15.7 K (-60.83 %) |
May 21 2018 | AGN | Allergan plc | Meury William | EVP & Chief Commerc ... | Buy | M | 68.11 | 19,785 | 1,347,556 | 40,154 | 20.4 K to 40.2 K (+97.13 %) |
May 21 2018 | AGN | Allergan plc | Meury William | EVP & Chief Commerc ... | Buy | M | 68.11 | 1,467 | 99,917 | 20,369 | 18.9 K to 20.4 K (+7.76 %) |
May 04 2018 | AGN | Allergan plc | COUGHLIN CHRISTOPHER J | Director | Grant | A | 151.07 | 1,985 | 299,874 | 6,431 | 4.4 K to 6.4 K (+44.65 %) |
May 04 2018 | AGN | Allergan plc | COUGHLIN CHRISTOPHER J | Director | Gift | G | 0.00 | 10,000 | 0 | 4,446 | 14.4 K to 4.4 K (-69.22 %) |
May 04 2018 | AGN | Allergan plc | KLEMA CATHY | Director | Grant | A | 151.07 | 1,985 | 299,874 | 25,624 | 23.6 K to 25.6 K (+8.40 %) |
May 04 2018 | AGN | Allergan plc | WEISS FRED G | Director | Grant | A | 151.07 | 1,985 | 299,874 | 29,675 | 27.7 K to 29.7 K (+7.17 %) |
May 04 2018 | AGN | Allergan plc | BISARO PAUL | Director | Grant | A | 151.07 | 1,985 | 299,874 | 263,729 | 261.7 K to 263.7 K (+0.76 %) |
May 04 2018 | AGN | Allergan plc | Boccuzi Joseph H | Director | Grant | A | 151.07 | 1,985 | 299,874 | 2,985 | 1,000 to 3 K (+198.50 %) |
May 04 2018 | AGN | Allergan plc | BODINE CHRIS W | Director | Grant | A | 151.07 | 1,985 | 299,874 | 18,495 | 16.5 K to 18.5 K (+12.02 %) |
May 04 2018 | AGN | Allergan plc | Brown Adriane M | Director | Grant | A | 151.07 | 1,985 | 299,874 | 2,796 | 811 to 2.8 K (+244.76 %) |
May 04 2018 | AGN | Allergan plc | McDonnell Peter J | Director | Grant | A | 151.07 | 1,985 | 299,874 | 6,232 | 4.2 K to 6.2 K (+46.74 %) |
May 04 2018 | AGN | Allergan plc | O'Sullivan Patrick J | Director | Grant | A | 151.07 | 1,985 | 299,874 | 6,633 | 4.6 K to 6.6 K (+42.71 %) |
May 04 2018 | AGN | Allergan plc | Basgoz Nesli | Director | Grant | A | 151.07 | 1,985 | 299,874 | 7,359 | 5.4 K to 7.4 K (+36.94 %) |
May 04 2018 | AGN | Allergan plc | DAVIDSON CAROL ANTHONY | Director | Grant | A | 151.07 | 1,985 | 299,874 | 1,985 | 0 to 2 K |
May 03 2018 | AGN | Allergan plc | Boccuzi Joseph H | Director | Payment of Exercise | F | 152.94 | 462 | 70,658 | 1,000 | 1.5 K to 1,000 (-31.60 %) |
May 03 2018 | AGN | Allergan plc | McDonnell Peter J | Director | Payment of Exercise | F | 152.94 | 588 | 89,929 | 4,247 | 4.8 K to 4.2 K (-12.16 %) |
May 03 2018 | AGN | Allergan plc | BODINE CHRIS W | Director | Payment of Exercise | F | 152.94 | 588 | 89,929 | 16,510 | 17.1 K to 16.5 K (-3.44 %) |
May 03 2018 | AGN | Allergan plc | Basgoz Nesli | Director | Payment of Exercise | F | 152.94 | 588 | 89,929 | 5,374 | 6 K to 5.4 K (-9.86 %) |
May 03 2018 | AGN | Allergan plc | Brown Adriane M | Director | Payment of Exercise | F | 152.94 | 588 | 89,929 | 811 | 1.4 K to 811 (-42.03 %) |
May 03 2018 | AGN | Allergan plc | BISARO PAUL | Director | Payment of Exercise | F | 152.94 | 588 | 89,929 | 261,744 | 262.3 K to 261.7 K (-0.22 %) |
May 03 2018 | AGN | Allergan plc | O'Sullivan Patrick J | Director | Payment of Exercise | F | 152.94 | 588 | 89,929 | 4,648 | 5.2 K to 4.6 K (-11.23 %) |
Apr 05 2018 | AGN | Allergan plc | Nicholson C. David | Chief R&D Officer | Payment of Exercise | F | 164.74 | 871 | 143,489 | 17,357 | 18.2 K to 17.4 K (-4.78 %) |
Apr 05 2018 | AGN | Allergan plc | Bailey A Robert D | Chief Legal Officer ... | Payment of Exercise | F | 164.74 | 581 | 95,714 | 23,922 | 24.5 K to 23.9 K (-2.37 %) |
Apr 05 2018 | AGN | Allergan plc | SAUNDERS BRENT L | Chairman, President ... | Payment of Exercise | F | 164.74 | 2,756 | 454,023 | 178,175 | 180.9 K to 178.2 K (-1.52 %) |
Apr 05 2018 | AGN | Allergan plc | Meury William | Chief Commercial Of ... | Payment of Exercise | F | 164.74 | 819 | 134,922 | 18,902 | 19.7 K to 18.9 K (-4.15 %) |
Apr 05 2018 | AGN | Allergan plc | Ling Karen | Chief Human Resourc ... | Payment of Exercise | F | 164.74 | 392 | 64,578 | 27,481 | 27.9 K to 27.5 K (-1.41 %) |
Apr 05 2018 | AGN | Allergan plc | Hilado Maria Teresa | Executive Vice Pres ... | Payment of Exercise | F | 164.74 | 619 | 101,974 | 25,911 | 26.5 K to 25.9 K (-2.33 %) |
Mar 20 2018 | AGN | Allergan plc | Swanton Wayne R | EVP, Global Operati ... | Payment of Exercise | F | 168.96 | 37 | 6,252 | 16,513 | 16.6 K to 16.5 K (-0.22 %) |
Mar 19 2018 | AGN | Allergan plc | Hilado Maria Teresa | Executive Vice Pres ... | Buy | P | 167.39 | 895 | 149,814 | 26,530 | 25.6 K to 26.5 K (+3.49 %) |
Mar 09 2018 | AGN | Allergan plc | DArecca James | Chief Accounting Of ... | Payment of Exercise | F | 153.50 | 79 | 12,127 | 5,600 | 5.7 K to 5.6 K (-1.39 %) |
Mar 09 2018 | AGN | Allergan plc | Swanton Wayne R | EVP, Global Operati ... | Payment of Exercise | F | 153.50 | 91 | 13,969 | 16,550 | 16.6 K to 16.6 K (-0.55 %) |
Mar 09 2018 | AGN | Allergan plc | Boccuzi Joseph H | Director | Gift | G | 0.00 | 400 | 0 | 1,462 | 1.9 K to 1.5 K (-21.48 %) |
Mar 09 2018 | AGN | Allergan plc | Boccuzi Joseph H | Director | Buy | P | 143.42 | 900 | 129,078 | 1,862 | 962 to 1.9 K (+93.56 %) |
Mar 08 2018 | AGN | Allergan plc | Swanton Wayne R | EVP, Global Operati ... | Payment of Exercise | F | 153.22 | 108 | 16,548 | 16,641 | 16.7 K to 16.6 K (-0.64 %) |
Mar 08 2018 | AGN | Allergan plc | DArecca James | Chief Accounting Of ... | Grant | A | 153.22 | 1,696 | 259,861 | 5,679 | 4 K to 5.7 K (+42.58 %) |
Mar 08 2018 | AGN | Allergan plc | DArecca James | Chief Accounting Of ... | Payment of Exercise | F | 153.22 | 93 | 14,249 | 3,983 | 4.1 K to 4 K (-2.28 %) |
Mar 08 2018 | AGN | Allergan plc | WALSH MATTHEW M | EVP, Chief Financia ... | Buy | P | 153.96 | 1,000 | 153,960 | 25,416 | 24.4 K to 25.4 K (+4.10 %) |
Mar 08 2018 | AGN | Allergan plc | SAUNDERS BRENT L | Chairman, President ... | Buy | P | 152.53 | 3,300 | 503,349 | 180,931 | 177.6 K to 180.9 K (+1.86 %) |
Mar 06 2018 | AGN | Allergan plc | DArecca James | Chief Accounting Of ... | Payment of Exercise | F | 148.73 | 70 | 10,411 | 4,076 | 4.1 K to 4.1 K (-1.69 %) |
Mar 06 2018 | AGN | Allergan plc | DArecca James | Chief Accounting Of ... | Payment of Exercise | F | 144.02 | 76 | 10,946 | 4,146 | 4.2 K to 4.1 K (-1.80 %) |
Mar 06 2018 | AGN | Allergan plc | Swanton Wayne R | EVP, Global Operati ... | Payment of Exercise | F | 148.73 | 150 | 22,310 | 16,749 | 16.9 K to 16.7 K (-0.89 %) |
Mar 06 2018 | AGN | Allergan plc | Swanton Wayne R | EVP, Global Operati ... | Payment of Exercise | F | 144.02 | 58 | 8,353 | 16,899 | 17 K to 16.9 K (-0.34 %) |
Mar 06 2018 | AGN | Allergan plc | BISARO PAUL | Director | Payment of Exercise | F | 148.73 | 2,921 | 434,440 | 262,332 | 265.3 K to 262.3 K (-1.10 %) |
Feb 22 2018 | AGN | Allergan plc | WALSH MATTHEW M | EVP, Chief Financia ... | Option Exercise | A | 0.00 | 28,021 | 0 | 28,021 | |
Feb 22 2018 | AGN | Allergan plc | WALSH MATTHEW M | EVP, Chief Financia ... | Buy | P | 160.94 | 2,000 | 321,880 | 24,416 | 22.4 K to 24.4 K (+8.92 %) |
Feb 22 2018 | AGN | Allergan plc | WALSH MATTHEW M | EVP, Chief Financia ... | Grant | A | 160.59 | 9,340 | 1,499,911 | 22,416 | 13.1 K to 22.4 K (+71.43 %) |
Feb 22 2018 | AGN | Allergan plc | WALSH MATTHEW M | EVP, Chief Financia ... | Grant | A | 160.59 | 13,076 | 2,099,875 | 13,076 | 0 to 13.1 K |
Feb 16 2018 | AGN | Allergan plc | Meury William | Chief Commercial Of ... | Option Exercise | M | 66.20 | 17,381 | 1,150,622 | 0 | |
Feb 16 2018 | AGN | Allergan plc | Meury William | Chief Commercial Of ... | Option Exercise | M | 66.20 | 1,510 | 99,962 | 0 | |
Feb 16 2018 | AGN | Allergan plc | Meury William | Chief Commercial Of ... | Option Exercise | M | 51.07 | 2,765 | 141,209 | 0 | |
Feb 16 2018 | AGN | Allergan plc | Meury William | Chief Commercial Of ... | Option Exercise | M | 51.07 | 1,957 | 99,944 | 0 |